Sunday, February 25, 2018

Tuesday, 19 September 2017 Divani Caravel Hotel

Agenda

Tuesday, September 19, 2017

08.30 - 09.00

Registration & Coffee

09.00 - 09.30

Welcome and Introductory Remarks

Εvangelos Filopoulos, President, Hellenic Cancer Society, Surgeon, Director, Breast Cancer Clinic "Agios Savvas"

Odysseas Zoras, MD, PhD FACS, Rector, University of Crete, Professor in Surgical Oncology, University of Crete, Medical School, Head of the Department of Surgical Oncology, University Hospital of Heraklion, Member of the BoD of the European Society of Surgical Oncology (ESSO), Past President of the Hellenic Society of Surgical Oncology (HSSO)

Theofilos Rozenberg, President of Hellenic Center for Disease Control and Prevention (KEELPNO)

09.30-11.30 SESSION 1 | CANCER MANAGEMENT: MOVING FORWARD IN THE POST CRISIS ERA
Chair

Konstantinos N. Syrigos, M.D., Ph.D., FCCP , Professor of Medicine & Medical Oncology, Head, 3rd Department of Medicine, Sotiria General Hospital, Athens School of Medicine, National & Kapodistrian University, GR, Adj. Professor of Medicine, Pittsburgh School of Medicine, USA, Vis. Professor of Thoracic Oncology, Yale School of Medicine, USA

Keynote speech

"Economics of Cancer research: An international perspective"

Panos Kanavos, BSc, MSc (Oxon), MSc (LSE), PhD, Deputy Director, London School of Economics (LSE) Health, Program Director, MSc International Health Policy, LSE Reader in International Health Policy in the Department of Social Policy, London School of Economics (LSE), Program Director of the Medical Technology Research Group (MTRG) at LSE Health

"Defining and Measuring the value in cancer care"

Dr. Vasilios Barbounis, President, Greek College of Senology, Medical Oncologist, Head, 3rd Department of Medical Oncology, "Metropolitan" Hospital, Athens, Greece

"The burden of Cancer for the National Healthcare System"

Ioannis Baskozos, Secretary General for Public Health, Ministry of Health

"Cancer Policy in Greece: Are innovative treatments really accessible? "

Athanassios Vozikis, Assistant Professor, Director of the Laboratory of Health Economics and Management, Economics Dept., School of Economics, Business and International Studies, University of Piraeus

"Access to Cancer Therapy -Pharma Industry perspective"

Paschal Apostolides, President of the Hellenic Association of Pharmaceutical Companies (SFEE), General Manager at AbbVie Pharmaceuticals S.A.

"Access to Cancer Therapy -Patient perspective"

Kathy Apostolidis, President - Hellenic Cancer Federation-ELL.O.K., Vice President of ECPC-European Cancer Patient Coalition

Q&A

11:30 - 12:00

Coffee break

12.00 - 13.00 SESSION 2 | DEFINING AN EVOLVED APPROACH TOWARDS CANCER TREATMENT
Chair

Zenia Saridaki-Zoras, MD, PhD, Medical Oncologist, Scientific Director, Oncology Department "Asklepios", Member of the Board of Directors of the Hellenic Society of Medical Oncology

"Chimeric antigen receptor (CAR) T-Cell & Gene therapies: the next generation treatment - Medical perspective: Confronting cancer from a different angle"

George Vassilopoulos, MD PhD, Professor of Hematology, University of Thessaly Medical School, Head, Division of Hematology Larisa University Hospital, Affiliate Investigator, Group Leader Cell and Gene Therapy Lab BRFAA, Athens

"Payer perspective: Access and affordability of new pharmaceutical solutions"

Hara Kani, Head of Medicines Administration Planning & Monitoring, Directorate of Medicines, National Organization for Health Services (EOPYY)

"Targeted therapies and Immunotherapies: Is monotherapy vs. combination the new dilemma?"

Amanda Psyrri, Associate Professor of Medical Oncology, National Kapodistrian University of Athens, Medical School, Chief of Oncology, Attikon University Hospital

Q&A

13.00 - 14.00

Lunch break

14.00 - 15.45 SESSION 3 | RARE CANCERS: QUALITY CANCER TREATMENT AND DIAGNOSIS FOR ALL
Chair

Maria Gazouli, PhD, Associate Professor of Molecular Biology, Medical School, National and Kapodistrian University of Athens

Keynote speech

"The uprising role of patient advocacy in rare cancers: research, health policy and access"

Jan Geissler, Director, European Patients' Academy on Therapeutic Innovation (EUPATI)

Keynote speech

"Surveillance of rare cancers: Which is the situation around Europe "

Peter Hohenberger, MD, PhD, Professor of Surgical Oncology, Mannheim University Medical Center, University of Heidelberg

"Joint Action for Rare Cancers: The role of ENRs and their impact in national Healthcare Organization"

Annalisa Trama, MD, Epidemiologist, National Cancer Institute, Milan, Italy

"The necessity of Registries"

Zenia Saridaki-Zoras, MD, PhD Medical Oncologist, Scientific Director of the Oncology Department "Asklepios", Member of the Board of Directors of the Hellenic Society of Medical Oncology

"Childhood Cancers"

Apostolos Pourtsidis, M.D., PhD, President, Hellenic Society of Pediatric Hematology- Oncology (HeSPHO), Director NHS, Oncology Department, 'P. and A. Kyriakou' Children's Hospital, Athens, Member of Clinical Research Council of European branch of International Society in Paediatric Oncology (SIOPE CRC), Collaborating Member of European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment (ExPO-r-Net)

"A success story "the case of GIST"

Ioannis Boukovinas, MD, PhD, PharmaD, Medical Oncologist, Head of Oncology Unit, "Bioclinic", Thessaloniki, Greece, President of the Hellenic Society of Medical Oncology (HeSMO)

Q&A

15.45 - 17.15 SESSION 4 | PERSONALIZED AND TARGETED THERAPIES FOR CANCER
Chair

Kyriakos Souliotis, Vice Rector and Associate Professor of Health Policy, University of Peloponnese, Faculty of Social and Political Sciences

"Accurate Risk Stratification in Cancer: A prerequisite for Precision Medicine"

Kostas Stamatopoulos, MD, Director, Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki

"The use of biomarkers in clinical act"

Ioannis Mountzios, MSc, PhD, Consultant Medical Oncologist, 251 Airforce General Hospital, Athens, Greece

"The role of Pharma R&D in personalized medicine"

Christos Antonopoulos, MD, PhD, Business Unit Director Oncology, AstraZeneca

"Scientific research and innovative personalized therapies"

Nektarios Tavernarakis, Professor of Molecular Systems Biology, Medical School, University of Crete, Chairman of the Board of Directors at the Foundation for Research and Technology Hellas (FORTH), Research Director, Institute of Molecular Biology and Biotechnology (IMBB)

"Ethical, legal, and social implications of genomic medicine"

Patrina Paparrigopoulou, Professor, Law School, University of Athens

Q&A

17.15 - 17.30

CONCLUDING REMARKS

The program is under development.

© 2018 Boussias Communications, all rights reserved. info@boussias.com, T:210 6617777, F:210 6617778

Designed by Boussias
New Media Team